GLP-1 agonists is currently approved as second/third-line therapy for T2DM patients with inadequate glycaemic control (HbA1c 7.0 or 53 mmol/mol) despite lifestyle modifications and first-line antihyperglycaemics (metformin/sulfonylurea/insulin)
[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Alexiadou K., Hartley A., Tan T.M.M., Khamis R
This is the best buy if you're starting out, or if your skin is prone to sensitivity
Dermatol Ther 32:e13051 Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferatoractivated receptors and liver X receptor- in humans: no alteration in adipose tissue of obese and NIDDM patients
Participants, investigators and other research personnel were blinded to allocation
Thnh phn v cng dng: Chit xut qu cu k t, d h tr tng cng h min dch v gim thiu tc hi t tia cc tm cho c th